BioDrugs · 2013 · 75 citations · 18 references
MedicinePharmacokineticsPharmacologyDrug DeliveryNeuro-ophthalmologyOcular PharmacologyNeuroprotectionOcular PharmacokineticsTopical Ocular Drug DeliveryTopical Ophthalmic MedicationsDrug Delivery To The EyeEye Drop TolerabilityNeurological Adverse EventsPhase I Clinical TrialsTotal Dose
BACKGROUND AND OBJECTIVES: Nerve growth factor (NGF) is a neurotrophin with therapeutic possibilities that extend from the nervous system to the eye. We tested the safety, maximal tolerated dose, pharmacokinetics, and antigenicity of a novel human recombinant NGF (rhNGF) eye-drop formulation in a phase I study. METHODS: This prospective, randomized, double-masked, vehicle-controlled trial, sponsored by Dompé SpA (registered as NCT01744704 at ClinicalTrials.gov), enrolled 74 healthy volunteers (24 females, 50 males, age 40.2 ± 11.8 years). Subjects were randomized in three cohorts to receive (1) a single eye-drop containing 0.0175, 0.175, or 0.7 μg rhNGF; (2) a single ascending dose of rhNGF eye drops three times a day for 1 day (total daily dose 2.1, 6.3, or 18.9 μg), or vehicle; or (3) a multiple ascending dose of rhNGF eye drops three times a day for 5 days (total dose 10.5, 31.5, or 94.5 μg), or vehicle. Outcome measures included blood chemistry, urinalyses, vital signs, electrocardiograms (ECGs), serum NGF antibodies, ocular and systemic adverse events (AEs), visual acuity, tear function, intraocular pressure, fundus oculi, and ocular symptoms. RESULTS: Administration of rhNGF eye drops did not result in a significant increase of circulating NGF levels and no antidrug antibodies were detected in serum. No serious AEs were recorded, and a few mild, transient ocular AEs related to rhNGF administration were reported only at the highest concentration. CONCLUSIONS: rhNGF eye drops were well tolerated, with no detectable clinical evidence of systemic AEs. These results pave the way for the development of clinical trials on rhNGF in ophthalmology.
18
p75 and Trk: A two-receptor system
Moses V. Chao, Barbara L. Hempstead · Trends in Neurosciences · 1995 · 862 citations
Human β-nerve growth factor gene sequence highly homologous to that of mouse
Axel Ullrich, Alane Gray, Cara Berman et al. · Nature · 1983 · 484 citations
Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic Ulcers
Alessandro Lambìase, Paolo Rama, Stefano Bonini et al. · New England Journal of Medicine · 1998 · 417 citations · Full text
Medicine, Dermatology, Ophthalmology +16